Epidemiological Profile of Crimean-Congo Hemorrhagic Fever in Thi-Qar Province, Iraq: A Three-Year Retrospective Analysis
International Journal of Medical Toxicology and Forensic Medicine,
Vol. 16 (2026),
1 January 2026
,
Page 1-7
https://doi.org/10.22037/ijmtfm.v16.51963
Abstract
Background: Crimean-Congo hemorrhagic fever (CCHF) is a severe disease. It is most commonly spread by the bite of an infected tick of the Hyalomma genus, or by direct contact with blood and bodily fluids of an infected person or other animals. The current study aimed to determine the prevalence of hemorrhagic fever cases during 3 years in Thi-Qar province and also study demographic factors.
Methods: Data were collected from the records of the Statistics Unit at the Public Health Laboratory. The epidemiological data were collected from the beginning of December 2023 to the end of March 2024.
Results: A total of 319 cases, which included 184 (57.7%) males and 135 (42.3%) females. The number of people recovered was 256 (80.3%), whereas the deceased cases recorded were 63 (19.7%). The highest rate of infection appeared in the age group of 20–39 years (41.4%), and the lowest proportion (11.0%) was in the ≥60 years age group. According to occupation, housewives were the highest proportion (37.9%). Total annual infections were recorded 4.7%, 50.8% and 44.5%, respectively.
Conclusion: The study highlighted the epidemiological features. The results indicate patterns in the distribution of cases across demographic and geographic variables. We conclude from the current study that occupational and home exposure, especially among housewives, are among the most common cases of hemorrhagic fever.
- Crimean-Congo hemorrhagic fever, Epidemiological, Viral hemorrhagic fevers, VHFs
How to Cite
References
[1] Rempe RG, Hartz AMS, Bauer B. Matrix metalloproteinases in the brain and blood–brain barrier: versatile breakers and makers. J Cereb Blood Flow Metab 2016;36:1481–507. [DOI: 10.1177/0271678X16655551]
[2] Lama A, Pirozzi C, Avagliano C, Annunziata C, Mollica MP, Calignano A, et al. Nutraceuticals: An integrative approach to starve Parkinson’s disease. Brain, Behav Immunity-Health 2020;2:100037. [DOI: 10.1016/j.bbih.2020.100037]
[3] Awad K, Abushouk AI, AbdelKarim AH, Mohammed M, Negida A, Shalash AS. Bee venom for the treatment of Parkinson’s disease: How far is it possible? Biomed Pharmacother 2017;91:295–302. [DOI: 10.1016/j.biopha.2017.04.065]
[4] Werner MH, Olanow CW. Parkinson’s disease modification through Abl kinase inhibition: an opportunity. Mov Disord 2022;37:6–15. [DOI: 10.1002/mds.28858]
[5] Thomas B, Beal MF. Parkinson’s disease. Hum Mol Genet 2007;16:R183–94. [DOI: 10.1093/hmg/ddm159]
[6] Titova N, Qamar MA, Chaudhuri KR. The nonmotor features of Parkinson’s disease. Int Rev Neurobiol 2017;132:33–54. [DOI: 10.1016/bs.irn.2017.02.016]
[7] Cetin S, Knez D, Gobec S, Kos J, Pišlar A. Cell models for Alzheimer’s and Parkinson’s disease: At the interface of biology and drug discovery. Biomed Pharmacother 2022;149:112924. [DOI: 10.1016/j.biopha.2022.112924]
[8] Presgraves SP, Ahmed T, Borwege S, Joyce JN. Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists. Neurotox Res 2003;5:579–98. [DOI: 10.1007/BF03033178]
[9] Hong N. Photobiomodulation as a treatment for neurodegenerative disorders: current and future trends. Biomed Eng Lett 2019;9:359–66. [DOI: 10.1007/s13534-019-00115-x]
[10] Karu TI. Multiple roles of cytochrome c oxidase in mammalian cells under action of red and IR‐A radiation. IUBMB Life 2010;62:607–10. [DOI: 10.1002/iub.359]
[11] Hamblin MR. Photobiomodulation or low-level laser therapy. J Biophotonics 2016;9:1122. [DOI: 10.1002/jbio.201670113]
[12] Han X, Han B, Zhao Y, Li G, Wang T, He J, et al. Rosmarinic acid attenuates rotenone-induced neurotoxicity in SH-SY5Y Parkinson’s disease cell model through Abl inhibition. Nutrients 2022;14:3508. [DOI: 10.3390/nu14173508]
[13] Liu Q, Wu H, Zhang H, Pan Y, Du S, Song W, et al. Heat shock protein is associated with inhibition of inflammatory cytokine production by 630 nm light-emitting diode irradiation in fibroblast-like synoviocytes based on RNA sequencing analysis. Photobiomodulation, Photomedicine, Laser Surg 2022;40:751–62. [DOI: 10.1089/photob.2022.0041]
[14] Chung H, Dai T, Sharma SK, Huang Y-Y, Carroll JD, Hamblin MR. The nuts and bolts of low-level laser (light) therapy. Ann Biomed Eng 2012;40:516–33. [DOI: 10.1007/s10439-011-0454-7]
[15] Li P, Lv H, Zhang B, Duan R, Zhang X, Lin P, et al. Growth differentiation factor 15 protects SH-SY5Y cells from rotenone-induced toxicity by suppressing mitochondrial apoptosis. Front Aging Neurosci 2022;14:869558. [DOI: 10.3389/fnagi.2022.869558]
[16] Pirunkaset E, Boonyarat C, Maneenet J, Khamphukdee C, Daodee S, Monthakantirat O, et al. Effect of diacetylcurcumin manganese complex on rotenone-induced oxidative stress, mitochondria dysfunction, and inflammation in the SH-SY5Y Parkinson’s Disease cell model. Molecules 2024;29:957. [DOI: 10.3390/molecules29050957]
[17] Ibarra-Gutiérrez MT, Serrano-García N, Orozco-Ibarra M. Rotenone-induced model of Parkinson’s disease: beyond mitochondrial complex I inhibition. Mol Neurobiol 2023;60:1929–48. [DOI: 10.1007/s12035-022-03193-8]
[18] Hörmann P, Delcambre S, Hanke J, Geffers R, Leist M, Hiller K. Impairment of neuronal mitochondrial function by L-DOPA in the absence of oxygen-dependent auto-oxidation and oxidative cell damage. Cell Death Discov 2021;7:151. [DOI: 10.1038/s41420-021-00547-4]
[19] Asanuma M, Miyazaki I, Ogawa N. Dopamine-or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease. Neurotox Res 2003;5:165–76.
[20] Huang Y-Y, Chen AC-H, Carroll JD, Hamblin MR. Biphasic dose response in low level light therapy. Dose Response 2009;7:358–83. [DOI: 10.2203/dose-response.09-027.Hamblin]
[21] Sharma SK, Kharkwal GB, Sajo M, Huang Y-Y, De Taboada L, McCarthy T, et al. Dose response effects of 810 nm laser light on mouse primary cortical neurons. Lasers Surg Med 2011;43:851–9. [DOI: 10.1002/lsm.21100]
[22] Chang S-Y, Lee MY, Chung P-S, Kim S, Choi B, Suh M-W, et al. Enhanced mitochondrial membrane potential and ATP synthesis by photobiomodulation increases viability of the auditory cell line after gentamicin-induced intrinsic apoptosis. Sci Rep 2019;9:19248. [DOI: 10.1038/s41598-019-55711-9]
[23] Shen Q, Guo H, Yan Y. Photobiomodulation for Neurodegenerative Diseases: A Scoping Review. Int J Mol Sci 2024;25. [DOI: 10.3390/ijms25031625]
[24] Salehpour F, Farajdokht F, Erfani M, Sadigh-Eteghad S, Shotorbani SS, Hamblin MR, et al. Transcranial near-infrared photobiomodulation attenuates memory impairment and hippocampal oxidative stress in sleep-deprived mice. Brain Res 2018;1682:36–43. [DOI: 10.1016/j.brainres.2017.12.040]
[25] Rossato RC, Salles GR, Albuquerque AL, Porcionatto MA, Granato AEC, Ulrich H, et al. Photobiomodulation by LED 660 nm and Taurine against H(2)O(2) oxidative stress in SH-SY5Y cells. Lasers Med Sci 2025;40:211. [DOI: 10.1007/s10103-025-04467-y]
[26] Li X, Wang X-K, Zhu Z-J, Liang Z-W, Li P-H, Ma Y-G, et al. Photobiomodulation provides neuroprotection through regulating mitochondrial fission imbalance in the subacute phase of spinal cord injury. Neural Regen Res 2023;18:2005–10. [DOI: 10.4103/1673-5374.366491]
[27] Hamblin MR. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophys 2017;4:337–61. [DOI: 10.3934/biophy.2017.3.337]
[28] Dos Santos Cardoso F, Mansur FCB, Araújo BHS, Gonzalez-Lima F, Gomes da Silva S. Photobiomodulation Improves the Inflammatory Response and Intracellular Signaling Proteins Linked to Vascular Function and Cell Survival in the Brain of Aged Rats. Mol Neurobiol 2022;59:420–8. [DOI: 10.1007/s12035-021-02606-4]
[29] Emdadul Haque M, Asanuma M, Higashi Y, Miyazaki I, Tanaka K, Ogawa N. Apoptosis-inducing neurotoxicity of dopamine and its metabolites via reactive quinone generation in neuroblastoma cells. Biochim Biophys Acta 2003;1619:39–52. [DOI: 10.1016/s0304-4165(02)00440-3]
[30] Pike AF, Longhena F, Faustini G, van Eik J-M, Gombert I, Herrebout MAC, et al. Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson’s disease. J Neuroinflammation 2022;19:50. [DOI: 10.1186/s12974-022-02410-4]
[31] Lee E, Hwang I, Park S, Hong S, Hwang B, Cho Y, et al. MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration. Cell Death Differ 2019;26:213–28. [DOI: 10.1038/s41418-018-0124-5]
[32] Farazi N, Salehi-Pourmehr H, Farajdokht F, Mahmoudi J, Sadigh-Eteghad S. Photobiomodulation combination therapy as a new insight in neurological disorders: a comprehensive systematic review. BMC Neurol 2024;24:101. [DOI: 10.1186/s12883-024-03593-4]
[33] Matt SM, Nolan R, Manikandan S, Agarwal Y, Channer B, Oteju O, et al. Dopamine-driven increase in IL-1β in myeloid cells is mediated by differential dopamine receptor expression and exacerbated by HIV. J Neuroinflammation 2025;22:91. [DOI: 10.1186/s12974-025-03403-9]
- Abstract Viewed: 14 times
- PDF Downloaded: 4 times